Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Godaddy Inc (GDDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Godaddy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Godaddy Inc trades at $87.83 (market cap $11.83B). The key difference: Godaddy Inc is far larger — about 2.6× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | GDDY | |
|---|---|---|
Market Cap | $4.49B | $11.83B |
Sector | Health | Technology |
52-Week High | $28.06 | $177.04 |
52-Week Low | $20.06 | $75.07 |
Enterprise Value | $3.69B | $14.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
GoDaddy (GDDY) trades at $89.32, up 0.92% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI signals. The company exhibits strong profitability with a 17.32% net income margin and consistent earnings beats, though revenue growth is moderating. Recent news highlights a securities class action investigation and optimism around AI resilience, with Q2 2026 results due July 30, 2026.
The stock presents a mixed outlook: analyst consensus is bullish with a $123 price target, but legal risks and high ROE from low equity base warrant caution. Upside hinges on execution amid competitive pressures, while any negative legal developments could pressure shares near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
